Plus Therapeutics(PSTV) - 2024 Q4 - Annual Results

Exhibit 99.1 Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights UPCOMING EXPECTED EVENTS AND MILESTONES FULL YEAR 2024 FINANCIAL RESULTS • Completed ReSPECT-LM Phase 1 single dose administration trial and determined the maximum feasible and recommended Phase 2 doses. Additional details can be found here • Presented positive ReSPECT-LM Phase 1 interim data for LM at the 2024 SNO Annual Conference. Additional details can be found here • Presented posit ...